Gilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of $143.09 billion. The enterprise value is $160.18 billion.
| Market Cap | 143.09B |
| Enterprise Value | 160.18B |
Important Dates
The next estimated earnings date is Thursday, April 24, 2025, after market close.
| Earnings Date | Apr 24, 2025 |
| Ex-Dividend Date | Mar 14, 2025 |
Share Statistics
Gilead Sciences has 1.25 billion shares outstanding. The number of shares has decreased by -0.24% in one year.
| Current Share Class | 1.25B |
| Shares Outstanding | 1.25B |
| Shares Change (YoY) | -0.24% |
| Shares Change (QoQ) | +0.40% |
| Owned by Insiders (%) | 0.10% |
| Owned by Institutions (%) | 87.39% |
| Float | 1.24B |
Valuation Ratios
The trailing PE ratio is 302.42 and the forward PE ratio is 14.47. Gilead Sciences's PEG ratio is 0.51.
| PE Ratio | 302.42 |
| Forward PE | 14.47 |
| PS Ratio | 5.03 |
| Forward PS | n/a |
| PB Ratio | 7.48 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.02 |
| P/OCF Ratio | 13.34 |
| PEG Ratio | 0.51 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.91, with an EV/FCF ratio of 15.54.
| EV / Earnings | 333.71 |
| EV / Sales | 5.57 |
| EV / EBITDA | 11.91 |
| EV / EBIT | 14.99 |
| EV / FCF | 15.54 |
Financial Position
The company has a current ratio of 1.60, with a Debt / Equity ratio of 1.42.
| Current Ratio | 1.60 |
| Quick Ratio | 1.33 |
| Debt / Equity | 1.42 |
| Debt / EBITDA | 2.01 |
| Debt / FCF | 2.65 |
| Interest Coverage | 10.94 |
Financial Efficiency
Return on equity (ROE) is 2.29% and return on invested capital (ROIC) is 14.07%.
| Return on Equity (ROE) | 2.29% |
| Return on Assets (ROA) | 11.03% |
| Return on Invested Capital (ROIC) | 14.07% |
| Return on Capital Employed (ROCE) | 22.74% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.47 |
| Inventory Turnover | 3.58 |
Taxes
In the past 12 months, Gilead Sciences has paid $211.00 million in taxes.
| Income Tax | 211.00M |
| Effective Tax Rate | 30.54% |
Stock Price Statistics
The stock price has increased by +58.69% in the last 52 weeks. The beta is 0.24, so Gilead Sciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | +58.69% |
| 50-Day Moving Average | 98.09 |
| 200-Day Moving Average | 83.83 |
| Relative Strength Index (RSI) | 75.16 |
| Average Volume (20 Days) | 8,326,733 |
Short Selling Information
The latest short interest is 21.16 million, so 1.70% of the outstanding shares have been sold short.
| Short Interest | 21.16M |
| Short Previous Month | 22.93M |
| Short % of Shares Out | 1.70% |
| Short % of Float | 1.70% |
| Short Ratio (days to cover) | 2.74 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of $28.75 billion and earned $480.00 million in profits. Earnings per share was $0.38.
| Revenue | 28.75B |
| Gross Profit | 22.50B |
| Operating Income | 10.69B |
| Pretax Income | n/a |
| Net Income | 480.00M |
| EBITDA | 13.45B |
| EBIT | 10.69B |
| Earnings Per Share (EPS) | $0.38 |
Balance Sheet
The company has $11.57 billion in cash and $27.32 billion in debt, giving a net cash position of -$15.75 billion or -$12.65 per share.
| Cash & Cash Equivalents | 11.57B |
| Total Debt | 27.32B |
| Net Cash | -15.75B |
| Net Cash Per Share | -$12.65 |
| Equity (Book Value) | 19.25B |
| Book Value Per Share | 15.51 |
| Working Capital | 7.17B |
Cash Flow
In the last 12 months, operating cash flow was $10.83 billion and capital expenditures -$523.00 million, giving a free cash flow of $10.31 billion.
| Operating Cash Flow | 10.83B |
| Capital Expenditures | -523.00M |
| Free Cash Flow | 10.31B |
| FCF Per Share | $8.27 |
Margins
Gross margin is 78.26%, with operating and profit margins of 37.17% and 1.67%.
| Gross Margin | 78.26% |
| Operating Margin | 37.17% |
| Pretax Margin | 2.40% |
| Profit Margin | 1.67% |
| EBITDA Margin | 46.79% |
| EBIT Margin | 37.17% |
| FCF Margin | 35.84% |
Dividends & Yields
This stock pays an annual dividend of $3.87, which amounts to a dividend yield of 3.37%.
| Dividend Per Share | $3.87 |
| Dividend Yield | 3.37% |
| Dividend Growth (YoY) | 2.65% |
| Years of Dividend Growth | 10 |
| Payout Ratio | 1,018.42% |
| Buyback Yield | 0.24% |
| Shareholder Yield | 0.24% |
| Earnings Yield | 0.33% |
| FCF Yield | 7.13% |
Analyst Forecast
The average price target for Gilead Sciences is $102.96, which is -10.39% lower than the current price. The consensus rating is "Buy".
| Price Target | $102.96 |
| Price Target Difference | -10.39% |
| Analyst Consensus | Buy |
| Analyst Count | 27 |
| Revenue Growth Forecast (5Y) | 3.24% |
| EPS Growth Forecast (5Y) | 91.04% |
Stock Splits
The last stock split was on January 28, 2013. It was a forward split with a ratio of 2:1.
| Last Split Date | Jan 28, 2013 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
Gilead Sciences has an Altman Z-Score of 2.96 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.96 |
| Piotroski F-Score | 7 |